Evidence map›Paper›PMID 38854003›Full record

ArticlebioRxiv : the preprint server for biology2024

Discovery of Potent Degraders of the Dengue Virus Envelope Protein.

Zhengnian Li, Han-Yuan Liu, Zhixiang He, Antara Chakravarty, Ryan P Golden, Zixuan Jiang, Inchul You, Hong Yue, Katherine A Donovan, Guangyan Du and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Zhengnian LiDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.ORCID 0009-0000-2365-8807
Han-Yuan LiuDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.
Zhixiang HeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Antara ChakravartyDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.
Ryan P GoldenDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Zixuan JiangDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Inchul YouDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Hong YueDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Guangyan DuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Jianwei CheDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Jason TseDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Isaac CheDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Wenchao LuDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Tinghu ZhangDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-0192-7118
Nathanael S GrayDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Priscilla L YangDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-5271-2603

Funding

Validating the Flavivirus Envelope Protein as an Antiviral TargetR01AI146152 · NIAID · STANFORD UNIVERSITY · PI GRAY, NATHANAEL SCHIANDER, YANG, PRISCILLA LI-NING · 2020 to 2024
$4.6M
Small molecule-induced degradation of dengue proteins as an antiviral strategyR01AI148632 · NIAID · STANFORD UNIVERSITY · PI GRAY, NATHANAEL SCHIANDER, YANG, PRISCILLA LI-NING · 2020 to 2024
$4.1M
NIAID NIH HHS R01 AI146152NIAID NIH HHS R01 AI148632
6 · The paper itself

Abstract

Targeted protein degradation has been widely adopted as a new approach to eliminate both established and previously recalcitrant therapeutic targets. Here we report the development of small molecule degraders of the envelope (E) protein of dengue virus. We developed two classes of bivalent E-degraders, linking two previously reported E-binding small molecules, GNF-2 and CVM-2-12-2, to a glutarimide-based recruiter of the CRL4

Indexed as

antiviralsdengueenvelope proteininfectionprotein degradation

Identifiers

PMID38854003
PMCPMC11160776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.